Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 13/20 | 0.42 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406987 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| SCHEMBL12585560 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| SCHEMBL1406650 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| SCHEMBL12585556 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| SCHEMBL1406989 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| SCHEMBL1994028 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| SCHEMBL12585707 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| SCHEMBL12585708 | 1.00 | EPHX2 (0.46) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| Water SCHEMBL4715563 | 0.97 | EPHX2 (0.44) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 | |
| Water SCHEMBL4715564 | 0.97 | EPHX2 (0.44) | EPHX2L3MBTL1GAAHSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916747-A | Fused heterocyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2431353-B1 | Process for preparing amine compound | KANTO KAGAKU (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-1999114-B1 | PYRAZOLES AS 11-BETA-HSD-1 | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2431353-A1 | Process for preparing amine compound | Kanto Kagaku Kabushiki Kaisha (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20120065426-A1 | PROCESS FOR PREPARING AMINE COMPOUND | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-03-15 | — | — | US | disclosed |
| US-7968601-B2 | Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| EP-2295411-A1 | Pyrazoles as 11-beta-hsd-1 | F. Hoffmann-La Roche AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1999114-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. Hoffmann-la Roche AG (CH) | 2008-12-10 | — | — | EP | disclosed |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | LINDERS JOANNES T M | 2008-04-24 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| WO-2007107470-A2 | PYRAZOLES AS 11-BETA-HSD-1 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICAL N.V. (BE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | EPHX2 936/4885L3MBTL1 4673/4885GAA 578/4885 |
| US-20120065426-A1 | PROCESS FOR PREPARING AMINE COMPOUND | PNMT, HNMT, GNMT | EPHX2 1034/4885L3MBTL1 4606/4885GAA 1053/4885 |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | DHCR7, HSD3B2, HSD3B1 | EPHX2 136/4885L3MBTL1 2850/4885GAA 4114/4885 |
| US-20060079506-A1 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | DHCR7, HSD3B2, HSD3B1 | EPHX2 136/4885L3MBTL1 2850/4885GAA 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.